MDMA, Or Ecstasy, Shows Promise As A PTSD Treatment
MDMA, the psychoactive ingredient in the club drug known as molly or ecstasy, is being tested in combination with therapy as a treatment for severe trauma.
Drugs
761-780 of 1,322 results
-
-
Among Hurdles For Those With Opioid Addictions: Getting The Drug To Treat It
It can be difficult to get a prescription for buprenorphine, one of the gold standards for treating opioid use disorder. And not all pharmacies stock the drug.
-
KHN’s ‘What The Health?’: We Answer Your Questions
You asked about drug prices, the “Cadillac tax” on generous insurance plans and why Americans don’t know that most other countries also have combination public-private insurance systems. This week, Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico and Caitlin Owens of Axios join KHN’s Julie Rovner to answer those questions.
-
Doctors Can Change Opioid Prescribing Habits, But Progress Comes In Small Doses
Research out Wednesday indicates that guidelines are making strides in cutting back the number of pain pills doctors offer after specific types of surgeries.
By Julie Appleby and Elizabeth Lucas -
KHN’s ‘What The Health?’: Gun Violence And The Politics Of Public Health
The recent tragic mass shootings have refocused efforts to treat gun violence as a public health issue rather than strictly a law enforcement problem. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Agnes Carey of Kaiser Health News join KHN’s Julie Rovner to discuss this, plus the health implications of the budget deal passed by Congress and signed by President Donald Trump, as well as reaction from Canada to a proposal to allow broader imports of its prescription drugs. Plus, for “extra credit,” the panelists recommend their favorite health stories of the week.
-
Price Of Snakebite Drug Is Sky High, But New Competitor Unlikely To Lower Costs
The drug CroFab, which has been on the market since 2000, now faces competition from a drug called Anavip. But both are expensive.
-
Federal Experts’ Advice On HPV Vaccine Could Leave Adults Confused
A federal advisory panel says people between ages 27 and 45 may benefit from the vaccine to fight the human papillomavirus. But some public health advocates worry that the advice doesn’t provide doctors and patients clear guidance about who in this large age group are good candidates for the vaccine.
-
Drugmakers Master Rolling Out Their Own Generics To Stifle Competition
Known as “authorized generics,” in-house spinoffs of brand-name drugs quietly undermine the competition.
By Jay Hancock and Sydney Lupkin -
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
-
Infusion Treatments — Needed or Not — Can Deplete Patients’ Wallets
When it comes to physician-administered infusion drugs, doctors sometimes have a financial reason for their choice and patients often aren’t aware of cheaper options.
-
Podcast
KHN’s ‘What The Health?’: Deciphering The Democrats’ Health Debate
Health care was a major topic at the Democratic presidential candidate debates in Detroit on Tuesday and Wednesday, but the focus on plan minutiae may have left viewers more confused than edified. Alice Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Caitlin Owens of Axios join KHN’s Julie Rovner to discuss the points made by the candidates plus a series of Trump administration health initiatives on drug prices and hospital shopping.
-
California Bill Would Fight Deals That Delay Generic Drugs
As California Attorney General Xavier Becerra cracks down on pharmaceutical companies he said paid competitors to delay generic versions of their drugs, he’s also pushing for legislation that would give his department tools to catch more of them. It’s the first of its kind in the nation.
-
Trump Administration ‘Open For Business’ On Drug Imports From Canada
HHS secretary announces a preliminary plan Wednesday to allow Americans to import certain lower-cost drugs from Canada. Manufacturers were quick to criticize the plan, saying it does not guarantee the safety of drugs coming into the country.
-
Trump Administration Moves To Make Health Care Costs More Transparent
The proposed rules would require hospitals to provide far more detail about the actual prices they charge insurers for patients’ care.
-
New Protocol For HIV Prevention Drug Reduces The Number Of Pills Required
Health officials and AIDS advocates in San Francisco have endorsed a new regimen for PrEP medication: to be taken only immediately before and after sex, thus reducing cost and potential side effects. The standard regimen is one pill a day for an open-ended period.
By David Tuller -
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
Klobuchar Says D.C. Has Enough Drug Lobbyists To Double-Team Lawmakers
The drug industry has the biggest lobbying war chest.
-
GOP Senators Distance Themselves From Grassley And Trump’s Efforts To Cut Drug Prices
Even some Republicans who supported a sweeping bipartisan bill to rein in drug costs may not back it in the Senate vote.
-
KHN’s ‘What The Health?’: Cue The Drug Price Debate
Democrats and Republicans on the Senate Finance Committee unveiled their long-awaited proposal to try to rein in prescription drug costs, even as bipartisan leaders of the other Senate committee that oversees health announced it would not bring its drug price bill to the Senate floor until fall. Paige Winfield Cunningham of The Washington Post, Rebecca Adams of CQ Roll Call and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this, plus court actions on health issues.
-
Summer Setbacks: The Long Road To Lower Drug Prices Hits Some Potholes
Efforts to control drug prices seemed on a glide path earlier this year after gaining traction at the White House and in Congress. But prospects today look less certain and highly controversial.